文献速递浆细胞疾病

POEMS综合征:2017年诊断、风险分层与管理更新

POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management.
PubMed 文献 · Am J Hematol · 2017-01-01

POEMS综合征是由潜在浆细胞肿瘤引起的副肿瘤综合征,主要诊断标准包括多神经根神经病、克隆性浆细胞疾病、硬化性骨病变、血管内皮生长因子升高及Castleman病。诊断需3条主要标准(必须含多神经根神经病和克隆性浆细胞疾病)加至少1条次要标准。风险分层基于临床表型而非分子标志,浆细胞疾病范围决定预后;局限性骨病变首选放疗,弥漫性或播散性病变需全身治疗。

要点

  • 诊断需3条主要标准(必须含多神经根神经病和克隆性浆细胞疾病)加至少1条次要标准
  • 髂嵴骨髓活检未发现浆细胞克隆者适合局部放疗,克隆广泛或播散者适合全身治疗
  • 局限性硬化性浆细胞瘤一线治疗为放疗,弥漫性病变或放疗后3-6个月进展者需全身治疗

核心结论

  • POEMS综合征诊断延误常见,因疾病罕见且易误诊为其他神经疾病,最常误诊为慢性炎性脱髓鞘性多神经根神经病。
  • 风险分层限于临床表型而非特定分子标志,临床标准数量无预后价值,但浆细胞疾病范围有预后价值。
  • 及时识别并实施支持治疗和针对浆细胞的治疗可获得最佳结局。

研究设计与样本

  • 本文为2017年更新的综述,汇总POEMS综合征的诊断标准、风险分层和治疗管理。

主要发现

  • 主要标准为多神经根神经病、克隆性浆细胞疾病、硬化性骨病变、血管内皮生长因子升高和Castleman病。
  • 次要特征包括器官肿大、内分泌病、特征性皮肤改变、视乳头水肿、血管外容量负荷过重和血小板增多。
  • 应区分POEMS综合征与Castleman病变异型,后者无克隆性浆细胞疾病且通常无或仅有轻微周围神经病,但具备数条次要诊断标准。

关键数值与推荐

  • 诊断需3条主要标准,其中必须包括多神经根神经病和克隆性浆细胞疾病,并至少1条次要标准。
  • 髂嵴骨髓活检未显示浆细胞克隆的患者适合局部放疗,克隆更广泛或播散者适合全身治疗。
  • 有优势硬化性浆细胞瘤者一线治疗为放疗;弥漫性硬化性病变或播散性骨髓受累者、以及放疗完成后3-6个月疾病进展者应接受全身治疗。
  • 皮质类固醇为暂时性治疗,烷化剂是主要治疗手段,可采用低剂量常规治疗或大剂量联合干细胞移植。
  • 来那度胺显示前景且毒性可控;沙利度胺和硼替佐米有活性,但需权衡加重周围神经病的风险;抗VEGF抗体的获益存在矛盾。

临床怎么用

  • 有优势硬化性浆细胞瘤者一线治疗为放疗。
  • 弥漫性硬化性病变或播散性骨髓受累者及放疗后3-6个月进展者应接受全身治疗。
  • 烷化剂为主要治疗手段,可采用低剂量常规治疗或大剂量联合干细胞移植;皮质类固醇为暂时性治疗。
  • 来那度胺显示前景且毒性可控;沙利度胺和硼替佐米有活性但需权衡加重周围神经病的风险;抗VEGF抗体获益存在矛盾。
  • 及时识别并实施支持治疗和针对浆细胞的治疗可获得最佳结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: POEMS syndrome is a paraneoplastic syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. Diagnoses are often delayed because the syndrome is rare and can be mistaken for other neurologic disorders, most commonly chronic inflammatory demyelinating polyradiculoneuropathy. POEMS syndrome should be distinguished from the Castleman disease variant of POEMS syndrome, which has no clonal PCD and typically little to no peripheral neuropathy but has several of the minor diagnostic criteria for POEMS syndrome. DIAGNOSIS: The diagnosis of POEMS syndrome is made with 3 of the major criteria, two of which must include polyradiculoneuropathy and clonal plasma cell disorder, and at least one of the minor criteria. RISK STRATIFICATION: Because the pathogenesis of the syndrome is not well understood, risk stratification is limited to clinical phenotype rather than specific molecular markers. The number of clinical criteria is not prognostic, but the extent of the plasma cell disorder is. Those patients with an iliac crest bone marrow biopsy that does not reveal a plasma cell clone are candidates for local radiation therapy; those with a more extensive or disseminated clone will be candidates for systemic therapy RISK-ADAPTED THERAPY: For those patients with a dominant sclerotic plasmacytoma, first-line therapy is irradiation. Patients with diffuse sclerotic lesions or disseminated bone marrow involvement and for those who have progression of their disease 3-6 months after completing radiation therapy should receive systemic therapy. Corticosteroids are temporizing, but alkylators are the mainstay of treatment, either in the form of low-dose conventional therapy or high dose with stem cell transplantation. Lenalidomide shows promise with manageable toxicity. Thalidomide and bortezomib also have activity, but their benefit needs to be weighed against their risk of exacerbating the peripheral neuropathy. The benefit of anti-VEGF antibodies is conflicting. Prompt recognition and institution of both supportive care measures and therapy directed against the plasma cell result in the best outcomes.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Dispenzieri A. POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management. Am J Hematol. 2017. PMID: 28699668. doi:10.1002/ajh.24802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。